Picture of Axonics logo

AXNX — Axonics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Axonics Inc expected to post a loss of 63  cents a share - Earnings Preview

* Axonics Inc  AXNX.OQ   AXNX.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 5. 
    * The Irvine California-based  company is expected to report
 a
32.0% increase in revenue to $45.365 million from $34.37 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Axonics Inc is for
a loss
of 63 cents per share. For the same quarter last year, the
company reported a loss of 46 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Axonics Inc
is
$71​, above​ its last closing price of $57.74. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.37       -0.37      -0.34     Beat    8.1
 Sep. 30 2021  -0.43       -0.43      -0.38     Beat    11.9
 Jun. 30 2021  -0.48       -0.49      -0.59     Missed  -20.2​
 Mar. 31 2021  -0.41       -0.41      -0.46     Missed  -12.7
 ​​Dec.        -0.31       -0.31      -0.29     Beat    6.1
 31 2020                                                
 Sep. 30 2020  -0.51       -0.50      -0.24     Beat    52.1​
 Jun. 30 2020  -0.70       -0.69      -0.54     Beat    21.7
 Mar. 31 2020  -0.60       -0.60      -0.43     Beat    28.2
 This summary was machine generated May 4 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Axonics

See all news